Autres langues Revvity, Inc.

Actions

RVTY

US7140461093

Equipement et technologie médicale avancés

Marché Fermé - NYSE 22:00:02 25/09/2026			Varia. 5j.	Varia. 1 janv.
151,11 ^USD	+0,29%		+5,34%	+56,19%

24/09	Les principales informations de la mi-séance : retard du centre de données d’Oracle, retrait de l’offre de People sur MGM et nouveau test du diabète de Revvity	MT
24/09	Revvity, Inc. lance le kit GSP® T1D 3plex pour la détection précoce du diabète de type 1	CI

Autres langues

24/09	Sector Update: Healthcare Stocks Advance Late Afternoon
24/09	Top Midday Stories: Oracle's Data Center Delay; People Withdraws MGM Offer; Revvity's New Diabetes Test
24/09	Revvity, Inc. Launches GSP® T1D 3plex Kit For Early Detection Of Type 1 Diabetes
24/09	Revvity Shares Rise on Launch of Child Type 1 Diabetes Screening Test
24/09	Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes
21/09	Analystenempfehlungen: VAT, Porsche, Adidas, CoreWeave, eBay, Meta Platforms…
21/09	Analyst recommendations: Flutter, Constellation Brands, CoreWeave, eBay, Meta Platforms…
18/09	S&P 500 Posts Slight Weekly Decline as Utilities Weigh
09/09	Revvity, Inc. entered into a definitive agreement to acquire Human Cell Design SAS.
09/09	Revvity to Acquire Human Cell Design
09/09	Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery
04/09	Analystenempfehlungen: Volkswagen, Daimler Truck, OMV, Microsoft, Lululemon, Zscaler…
04/09	Analyst recommendations: Microsoft, DocuSign, Intuit, Lululemon Athletica, Zscaler…
01/09	Revvity Faces Growth Challenges Amid Rising Competition, RBC Says
11/08	Revvity : Quarterly Report for Quarter Ending July 5, 2026 (Form 10-Q)
11/08	Tranche Update on Revvity, Inc.'s Equity Buyback Plan announced on October 27, 2025.
11/08	Revvity to Present at Upcoming Investor Conferences
10/08	Revvity Launches Superflex Prenatal Screening System
05/08	Analyst recommendations: Palantir Technologies, McDonald's, Booking Holdings, Arista Networks, Amgen...
04/08	Revvity, Inc. Provides Earnings Guidance for the Full Year 2026
04/08	Revvity, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 05, 2026
04/08	Revvity Fiscal Q2 Adjusted Earnings, Revenue Rise; Fiscal 2026 Outlook Raised
04/08	Revvity raises annual profit, revenue forecasts on strong diagnostics demand
04/08	(RVTY) Revvity Expects Full Year 2026 Revenue Range $2.83B-$2.86B, vs. FactSet Est of $2.83B
04/08	(RVTY) Revvity Expects 2026 Adjusted EPS Range $5.30-$5.40, vs. FactSet Est of $5.24